Publicaciones (754) Publicaciones de Santiago Moreno Guillén

2024

  1. (, 10.2139/ssrn.4579870)

    Frontiers in Immunology

  2. A Phase I/IIa Prospective, Randomized, Open-Label Study on the Safety and Efficacy of Nebulized Liposomal Amphotericin for Invasive Pulmonary Aspergillosis

    Journal of Fungi, Vol. 10, Núm. 3

  3. Author Correction: Microbiome-derived cobalamin and succinyl-CoA as biomarkers for improved screening of anal cancer (Nature Medicine, (2023), 29, 7, (1738-1749), 10.1038/s41591-023-02407-3)

    Nature Medicine

  4. CD4/CD8 ratio and CD8+ T-cell count as prognostic markers for non-AIDS mortality in people living with HIV. A systematic review and meta-analysis

    Frontiers in Immunology, Vol. 15

  5. COVID-19: On the threshold of the fifth year. The situation in Spain

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 37, Núm. 1, pp. 17-28

  6. Decalogue to promote the implementation and improvement of recommendations for the early diagnosis of HIV in Emergency Departments

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 42, Núm. 5, pp. 267-271

  7. Effectiveness and Safety of Direct-acting Antivirals for Treatment of Adolescents With HCV/HIV Coinfection: Real-world Data From Europe

    Pediatric Infectious Disease Journal, Vol. 43, Núm. 5, pp. E155-E159

  8. Feasibility of a selective targeted strategy of HIV testing in emergency departments: a before-after study

    European Journal of Emergency Medicine, Vol. 31, Núm. 1, pp. 29-38

  9. Real-life application of a stratification model for HIV care

    Enfermedades Infecciosas y Microbiologia Clinica

  10. Respiratory syncytial virus: A new era

    Revista Espanola de Quimioterapia, Vol. 37, Núm. 2, pp. 134-148

  11. Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials

    The Lancet HIV, Vol. 11, Núm. 2, pp. e75-e85

2023

  1. A Risk Assessment Tool for Predicting Fragility Fractures in People with HIV: Derivation and Internal Validation of the FRESIA Model

    Journal of Bone and Mineral Research, Vol. 38, Núm. 10, pp. 1443-1452

  2. A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease

    Frontiers in Immunology, Vol. 14

  3. Advantages and disadvantages of maintaining the mandatory use of masks in health centers and nursing homes in Spain. How and when is it justified to maintain it?

    Revista Espanola de Quimioterapia, Vol. 36, Núm. 5, pp. 466-469

  4. Author Correction: Differential abundance of lipids and metabolites related to SARS-CoV-2 infection and susceptibility (Scientific Reports, (2023), 13, 1, (15124), 10.1038/s41598-023-40999-5)

    Scientific Reports

  5. CD4/CD8 Ratio During Human Immunodeficiency Virus Treatment: Time for Routine Monitoring?

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 76, Núm. 9, pp. 1688-1696

  6. Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain

    Infectious Diseases and Therapy, Vol. 12, Núm. 8, pp. 2039-2055

  7. Comparison of the Fecal Bacteriome of HIV-Positive and HIV-Negative Older Adults

    Biomedicines, Vol. 11, Núm. 8

  8. Contribution of Low CD4 Cell Counts and High Human Immunodeficiency Virus (HIV) Viral Load to the Efficacy of Preferred First-Line Antiretroviral Regimens for Treating HIV Infection: A Systematic Review and Meta-Analysis

    Clinical Infectious Diseases, Vol. 76, Núm. 11, pp. 2027-2037

  9. Controversies in the Design of Strategies for the Cure of HIV Infection

    Pathogens, Vol. 12, Núm. 2